The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid/low-dose naltrexone protocol
- PMID: 16484716
- DOI: 10.1177/1534735405285901
The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid/low-dose naltrexone protocol
Abstract
The authors describe the long-term survival of a patient with pancreatic cancer without any toxic adverse effects. The treatment regimen includes the intravenous alpha-lipoic acid and low-dose naltrexone (ALA-N) protocol and a healthy lifestyle program. The patient was told by a reputable university oncology center in October 2002 that there was little hope for his survival. Today, January 2006, however, he is back at work, free from symptoms, and without appreciable progression of his malignancy. The integrative protocol described in this article may have the possibility of extending the life of a patient who would be customarily considered to be terminal. The authors believe that life scientists will one day develop a cure for metastatic pancreatic cancer, perhaps via gene therapy or another biological platform. But until such protocols come to market, the ALA-N protocol should be studied and considered, given its lack of toxicity at levels reported. Several other patients are on this treatment protocol and appear to be doing well at this time.
Similar articles
-
The Long-Term Survival of a Patient With Stage IV Renal Cell Carcinoma Following an Integrative Treatment Approach Including the Intravenous α-Lipoic Acid/Low-Dose Naltrexone Protocol.Integr Cancer Ther. 2018 Sep;17(3):986-993. doi: 10.1177/1534735417747984. Epub 2017 Dec 19. Integr Cancer Ther. 2018. PMID: 29258346 Free PMC article.
-
Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases.Integr Cancer Ther. 2009 Dec;8(4):416-22. doi: 10.1177/1534735409352082. Integr Cancer Ther. 2009. PMID: 20042414
-
[Efficacy of gemcitabine combined oxaliplatin on advanced pancreatic cancer].Ai Zheng. 2007 Dec;26(12):1381-4. Ai Zheng. 2007. PMID: 18076807 Chinese.
-
Long-term survival in metastatic pancreatic cancer. A case report and review of the literature.JOP. 2006 Sep 10;7(5):486-91. JOP. 2006. PMID: 16998247 Review.
-
The multidisciplinary management of gastrointestinal cancer. Pancreatic cancer: from pathogenesis to cure.Best Pract Res Clin Gastroenterol. 2007;21(6):997-1014. doi: 10.1016/j.bpg.2007.10.025. Best Pract Res Clin Gastroenterol. 2007. PMID: 18070700 Review.
Cited by
-
Antagonists of the Mu-Opioid Receptor in the Cancer Patient: Fact or Fiction?Curr Oncol Rep. 2022 Oct;24(10):1337-1349. doi: 10.1007/s11912-022-01295-z. Epub 2022 Jun 1. Curr Oncol Rep. 2022. PMID: 35648340 Free PMC article. Review.
-
Naltrexone's Impact on Cancer Progression and Mortality: A Systematic Review of Studies in Humans, Animal Models, and Cell Cultures.Adv Ther. 2021 Feb;38(2):904-924. doi: 10.1007/s12325-020-01591-9. Epub 2020 Dec 18. Adv Ther. 2021. PMID: 33337537 Review.
-
The effect of naltrexone as a carboplatin chemotherapy-associated drug on the immune response, quality of life and survival of dogs with mammary carcinoma.PLoS One. 2018 Oct 4;13(10):e0204830. doi: 10.1371/journal.pone.0204830. eCollection 2018. PLoS One. 2018. PMID: 30286124 Free PMC article.
-
Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.Med Sci (Basel). 2018 Sep 21;6(4):82. doi: 10.3390/medsci6040082. Med Sci (Basel). 2018. PMID: 30248938 Free PMC article. Review.
-
The Long-Term Survival of a Patient With Stage IV Renal Cell Carcinoma Following an Integrative Treatment Approach Including the Intravenous α-Lipoic Acid/Low-Dose Naltrexone Protocol.Integr Cancer Ther. 2018 Sep;17(3):986-993. doi: 10.1177/1534735417747984. Epub 2017 Dec 19. Integr Cancer Ther. 2018. PMID: 29258346 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical